An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Trial Profile

An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2017

At a glance

  • Drugs Rogaratinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 May 2018 to 29 Mar 2019.
    • 16 Mar 2017 Planned primary completion date changed from 1 Mar 2018 to 31 Jan 2019.
    • 18 Feb 2017 Results (n=67) of the phase I expansion cohort in patients with urothelial bladder cancer selected using novel RNA-based approaches, presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top